Showing 6871-6880 of 7741 results for "".
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF
- National Rosacea Society Awards New Grants; Call for 2018 Proposalshttps://practicaldermatology.com/news/national-rosacea-society-awards-new-grants/2458008/The National Rosacea Society (NRS) awarded funding for three new studies, in addition to continuing support for three ongoing studies, as part of its research grants program. Dr. Benjamin Kaffenberger, MD assistant professor of dermatology at the Ohio
- FDA Approves Injection of Restylane Silk via Cannula for Lip Augmentationhttps://practicaldermatology.com/news/fda-approves-injection-of-restylane-silk-via-cannula-for-lip-augmentation/2458012/The FDA has approved the use of a small blunt tip cannula with Galderma's Restylane Silk for lip augmentation. Restylane Silk was the first FDA-approved hyaluronic acid (HA) dermal filler specifically designed for lip augmentation and the smoothing of wrinkles around the mouth in patients 21
- Biofrontera Appoints Jeffrey Holm as VP of Marketinghttps://practicaldermatology.com/news/biofrontera-appoints-jeffrey-holm-as-vp-of-marketing/2458013/Biofrontera AG, which specializes in the treatment of sun-induced skin cancer, has appointmented Jeffrey Holm as Vice President of Marketing, to further strengthen its US commercialization activities.
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- ASDS Cutting Edge Research Grants Awardedhttps://practicaldermatology.com/news/asds-cutting-edge-research-grants-awarded/2458019/The American Society for Dermatologic Surgery (ASDS) awarded a total of $96,669 to ei
- Omar A. Ibrahimi, MD, PhD, Wins ASDS Award for Outstanding Servicehttps://practicaldermatology.com/news/omar-a-ibrahimi-md-phd-wins-asds-award-for-outstanding-service/2458022/Omar A. Ibrahimi, MD, PhD, of Stamford, Connecticut, took home the 2017
- Dermavant Sciences Appoints Vince Ippolito as President and COOhttps://practicaldermatology.com/news/dermavant-sciences-appoints-vince-ippolito-as-president-and-coo/2458034/Dermavant Sciences, a biopharmaceutical company focused on developing therapies for dermatologic conditions, appointed Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito
- Castle Creek Pharmaceuticals Unveils First-Ever IGA Scale for EBS Clinical Researchhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-unveils-first-ever-iga-scale-for-ebs-clinical-research/2458035/Castle Creek Pharmaceuticals (CCP) has developed and validated the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical tria
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad